These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 24553347)

  • 1. Activity of a group B oncolytic adenovirus (ColoAd1) in whole human blood.
    Di Y; Seymour L; Fisher K
    Gene Ther; 2014 Apr; 21(4):440-3. PubMed ID: 24553347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro analysis of cidofovir and genetically engineered TK expression as potential approaches for the intervention of ColoAd1-based treatment of cancer.
    Bauzon M; Jin F; Kretschmer P; Hermiston T
    Gene Ther; 2009 Sep; 16(9):1169-74. PubMed ID: 19458647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Directed evolution generates a novel oncolytic virus for the treatment of colon cancer.
    Kuhn I; Harden P; Bauzon M; Chartier C; Nye J; Thorne S; Reid T; Ni S; Lieber A; Fisher K; Seymour L; Rubanyi GM; Harkins RN; Hermiston TW
    PLoS One; 2008 Jun; 3(6):e2409. PubMed ID: 18560559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer.
    Hemminki O; Diaconu I; Cerullo V; Pesonen SK; Kanerva A; Joensuu T; Kairemo K; Laasonen L; Partanen K; Kangasniemi L; Lieber A; Pesonen S; Hemminki A
    Mol Ther; 2012 Sep; 20(9):1821-30. PubMed ID: 22871667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolytic adenovirus: A tool for cancer therapy in combination with other therapeutic approaches.
    Goradel NH; Mohajel N; Malekshahi ZV; Jahangiri S; Najafi M; Farhood B; Mortezaee K; Negahdari B; Arashkia A
    J Cell Physiol; 2019 Jun; 234(6):8636-8646. PubMed ID: 30515798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel capsid-modified oncolytic recombinant adenovirus type 5 for tumor-targeting gene therapy by intravenous route.
    Wang Z; Yu B; Wang B; Yan J; Feng X; Wang Z; Wang L; Zhang H; Wu H; Wu J; Kong W; Yu X
    Oncotarget; 2016 Jul; 7(30):47287-47301. PubMed ID: 27323824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of biodistribution of a fiber-chimeric, conditionally replication-competent (oncolytic) adenovirus in CD46 receptor transgenic mice.
    Ganesh S; Gonzalez-Edick M; Gibbons D; Waugh J; Van Roey M; Jooss K
    Hum Gene Ther; 2009 Oct; 20(10):1201-13. PubMed ID: 19572803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modification of oncolytic adenovirus and its application in cancer therapy.
    Liang Y; He J; Zhao Y
    Discov Med; 2020; 30(161):129-144. PubMed ID: 33593481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. pH-sensitive oncolytic adenovirus hybrid targeting acidic tumor microenvironment and angiogenesis.
    Choi JW; Jung SJ; Kasala D; Hwang JK; Hu J; Bae YH; Yun CO
    J Control Release; 2015 May; 205():134-43. PubMed ID: 25575865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications.
    Uusi-Kerttula H; Hulin-Curtis S; Davies J; Parker AL
    Viruses; 2015 Nov; 7(11):6009-42. PubMed ID: 26610547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus.
    Kanerva A; Nokisalmi P; Diaconu I; Koski A; Cerullo V; Liikanen I; Tähtinen S; Oksanen M; Heiskanen R; Pesonen S; Joensuu T; Alanko T; Partanen K; Laasonen L; Kairemo K; Pesonen S; Kangasniemi L; Hemminki A
    Clin Cancer Res; 2013 May; 19(10):2734-44. PubMed ID: 23493351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolving Status of Clinical Immunotherapy with Oncolytic Adenovirus.
    Farrera-Sal M; Moya-Borrego L; Bazan-Peregrino M; Alemany R
    Clin Cancer Res; 2021 Jun; 27(11):2979-2988. PubMed ID: 33526422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concepts in Oncolytic Adenovirus Therapy.
    Mantwill K; Klein FG; Wang D; Hindupur SV; Ehrenfeld M; Holm PS; Nawroth R
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent antitumor effect of neurotensin receptor-targeted oncolytic adenovirus co-expressing decorin and Wnt antagonist in an orthotopic pancreatic tumor model.
    Na Y; Choi JW; Kasala D; Hong J; Oh E; Li Y; Jung SJ; Kim SW; Yun CO
    J Control Release; 2015 Dec; 220(Pt B):766-82. PubMed ID: 26471393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic Administration and Targeted Delivery of Immunogenic Oncolytic Adenovirus Encapsulated in Extracellular Vesicles for Cancer Therapies.
    Garofalo M; Villa A; Rizzi N; Kuryk L; Mazzaferro V; Ciana P
    Viruses; 2018 Oct; 10(10):. PubMed ID: 30322158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mining the adenovirus "virome" for systemic oncolytics.
    Barry MA; Weaver EA; Chen CY
    Curr Pharm Biotechnol; 2012 Jul; 13(9):1804-8. PubMed ID: 21740366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined fiber modifications both to target α(v)β(6) and detarget the coxsackievirus-adenovirus receptor improve virus toxicity profiles in vivo but fail to improve antitumoral efficacy relative to adenovirus serotype 5.
    Coughlan L; Vallath S; Gros A; Giménez-Alejandre M; Van Rooijen N; Thomas GJ; Baker AH; Cascalló M; Alemany R; Hart IR
    Hum Gene Ther; 2012 Sep; 23(9):960-79. PubMed ID: 22708837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids.
    Hamdan F; Ylösmäki E; Chiaro J; Giannoula Y; Long M; Fusciello M; Feola S; Martins B; Feodoroff M; Antignani G; Russo S; Kari O; Lee M; Järvinen P; Nisen H; Kreutzman A; Leusen J; Mustjoki S; McWilliams TG; Grönholm M; Cerullo V
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34362830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defects in innate immunity render breast cancer initiating cells permissive to oncolytic adenovirus.
    Ahtiainen L; Mirantes C; Jahkola T; Escutenaire S; Diaconu I; Osterlund P; Kanerva A; Cerullo V; Hemminki A
    PLoS One; 2010 Nov; 5(11):e13859. PubMed ID: 21079774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus.
    Diaconu I; Cerullo V; Hirvinen ML; Escutenaire S; Ugolini M; Pesonen SK; Bramante S; Parviainen S; Kanerva A; Loskog AS; Eliopoulos AG; Pesonen S; Hemminki A
    Cancer Res; 2012 May; 72(9):2327-38. PubMed ID: 22396493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.